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Abstract. Integrins from the very late activation anti-
gen (VLA) subfamily are involved in cellular attach-
ment to extracellular matrix (ECM) proteins and in
intercellular adhesions. It is known that the interaction
of integrin proteins with their ligands can be regulated
during cellular activation. We have investigated the
regulation of different VLA-mediated adhesive interac-
tions through the common 01 chain. We have found
that certain anti-01 antibodies strongly enhance bind-
ing of myelomonocytic U-937 cells to fibronectin. This
ßl-mediated regulatory effect involved both VLA-4
and VLA-5 fibronectin receptors. Moreover, anti-ßl
mAb also induced VLA-4-mediated binding to a re-
combinant soluble form of its endothelial cell ligand
VCAM-1. Non-activated peripheral blood T lympho-
cytes, unable to mediate VLA-4 interactions with fibro-
nectin or VCAM-1, acquired the ability to bind these
ligands in the presence of anti-01 mAb. The anti-01-
mediated changes in the affinities of 01 integrin for
their ligands were comparable to those triggered by
different lymphocyte activation agents such as anti-
CD3 mAb or phorbol esters . Adhesion of melanoma
NTEGRCNS constitute a family of widespread aß hetero-
dimeric adhesion receptors that mediatecell attachment
to extracellular matrix (ECM)' Proteins as well as
cell-cell interactions (29, 57). The very late activation
(VLA) antigen subfamily ofintegrins is composed ofacom-
mon ßl chain noncovalently associated with one ofat least
eight different a chains (8, 24, 36). Recent findings ofnovel
associations betweena chains and alternativeß subunits ex-
pand the VLA molecular and functional repertoire (7, 24,
26, 60).
The VLA members functionally behave as receptors for
differentECM proteins. Thus, the integrins VLA-2, VLA-5,
1. Abbreviations used in this paper: cAMP, cyclic adenosine monophos-
phate; COL, collagen; ECM, extracellular matrix; ELAM-1, endothelial
leukocyte adhesion molecule-1; EPA, N-ethyl,N-propyl amiloride; FN,
fibronectin; HUVEC, human umbilical veinendothelial cells; LEA-1, leuko-
cyte function associated antigen-1; LN, laminin; PKC, protein kinase C;
PMA, phorbol myristate acetate; TNF, tumor necrosis factor; VCAM-1,
vascular cell adhesion molecule-1; VLA, very late activation antigen; VN,
vitronectin.
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cells to other ECM proteins such as laminin or col-
lagen as well as that of a2-transfected K-562 cells to
collagen, was also strongly enhanced by anti-ßl mAb.
These 01-mediated regulatory effects on different
VLA-ligand interactions do not involve changes in cell
surface membrane expression of different VLA hetero-
dimers. The anti-01-mediated functional effects required
an active metabolism, cytoskeleton integrity and the
existence of physiological levels of intracellular cal-
cium as well as a functional Na+/H+ antiporter. 01 an-
tibodies not only increased cell attachment but also
promoted spreading and cytoplasmic extension of en-
dothelial cells on plates coated with either fibronectin,
collagen, or laminin as well as induced the rapid ap-
pearance of microspikes in U-937 cells on fibronectin.
Moreover, both 01 integrin and the cytoskeletal protein
talin colocalized in the anti-ßl induced microspikes.
These results emphasize the central role of the com-
mon 01 chain in regulating different adhesive func-
tions mediated by VLA integrins as well as cellular
morphology.
and VLA-6 are prototype receptors for collagen type I,
fibronectin and laminin, respectively (48, 55, 61). Other
VLAheterodimers such as VLA1 andVLA-3 canbindmore
than one ECMcomponent(19, 31, 35). Very recently, VLA-3
has been also implicated in epidermal cell-matrix contacts
by interacting with a novel ligand, termed epiligrin (13).
VLA-4 is involvedin both cell-cell andcell-ECM adhesive
interactions (5, 11, 27, 47, 62), since itcan bind fibronectin
in an RGD-independent manner, and is alsoable to interact
with a cell surface molecule, termed VCAM-1, on activated
endothelial cells (18).
The a chains of VLA integrins were thought to confer
the specificity for the recognition of the different ligands,
whereas thecommon 01 chain was suggestedto be involved
in signal transduction (22, 65). Recently, it has been found
that both aandß chains contribute toboth ligand and bind-
ing events (6, 33, 52, 63, 66). Previous studies have docu-
mented thatcellularactivation increases the affinity ofdiffer-
ent integrin proteins for their corresponding ligands (17, 53,
65954, 64). The involvement of the 02 chainofleukocyte integ-
rins in regulating the affinity of these interactions has been
postulated (21). Furthermore, evidence indicating that the li-
gand affinities of ßl integrins can be modulated on develop-
ing retinal neurons through the $1 subunit has been recently
reported (42) .
In this study, we have investigated the possible role of the
common 01 subunit of VLA integrins in the regulation of
adhesive functions of different heterodimers. We have found
that anti-ßl mAb can promote binding of distinct VLAaß
heterodimers to both ECM and cellular ligands.
Materials and Methods
Cells and Cell Cultures
U-937 myelomonocytic cell line was obtained from American Type Culture
Collection (Rockville, MD) and grown in RPMI 1640 medium (Flow
Laboratories, Irvine, Scotland) supplemented with 5 % FCS (Flow Labora-
tories), 2 mM L-glutamine, 50 U/ml penicillin, and 50 pg/ml streptomycin
(Flow Laboratories) . A375 melanoma cell line (34) was grown in MEM
(Flow Laboratories) supplemented with 10% FCS, 10 mM Hepes buffer,
essential aminoacids, vitamins, and antibiotics (Flow Laboratories).
Human umbilical vein endothelial cells (HUVEC) were obtained as de-
scribed (15). Briefly, umbilical vein was cannulated, washed, and incubated
with 0.1% collagenase P (Boehringer Mannheim GmbH, Mannheim, Ger-
many) for 20 min at 37°C. Cells were put into flasks (Nunc, Roskilde, Den-
mark) and cultured in M199 medium (Flow Laboratories) supplemented
with 20% newborn calf serum, 50 kg/ml ofendothelial cell growth supple-
ment, 100 kg/ml heparin from porcine intestinal mucose (Sigma Chemical
Co., St. Louis, MO), 50 U/ml penicillin, 50 pg/ml streptomycin, and 2 .5
lag/ml fungizone. Cells within two passages were used. Cells were split 1:3
and detached witha solution of0.05 % Trypsinand 0.02 % EDTA (Flow Lab-
oratories) before using.
Peripheral blood T cells were obtained from heparinized venous blood
ofnormal voluntary donors. After Ficoll-Hypaque (Pharmacia Fine Chemi-
cals, Uppsala, Sweden) centrifugation, peripheral mononuclear cells were
depleted of adherent cells by two steps of adherence incubation in plastic
flasks (Costar, Cambridge, MA) at 37°C for 2 h. T cells were purified by
passage through a nylon wool column. T cell-enriched population con-
tained >90% CD3+ and <5% CD20+ and CD14+ cells.
a2- and a4-transfected K-562 cells have been previously reported (18)
and were grown in RPMI 1640 medium supplemented with 5 % FCS, 2 mM
L-glutamine, 50 hg/ml gentamicin, and with 1.5 mg/ml Geneticin (G-418 ;
Gibco Laboratories, Grand Island, NY) .
Reagents
Staurosporine, Quin-2a, Cytochalasin B, 2 DO-glucose, PMA, and the
Cat+ ionophore A23187 were purchased from Sigma. N-ethyl,N-propyl
amiloride (EPA) was a gift from Merck (Merck & Co. Inc., Darmstadt,
West Germany).
mAbs, F(ab')2andFabFragments
Anti-/3l chain Lial/2, Lia 1/5and Alex 1/4mAb and anti-CD43 TPl/36mAb
were obtained in our laboratory and their characteristics will be described
elsewhere. The anti-ßl TS2/16, A-1A5, P4C10 and K20 (3, 12, 25); the anti-
al TS2/7 (25), the anti-a2 PIE6 (12) and 12F1 (46), the anti-a3 P1B5 (61),
the anti-a4chain HP2/1(50), the antiVCAM-14B9(51) andtheanti-HLA-A,
B W6/32 (4) mAb have been previously described. The anti-a5 SAM-1 and
the anti-a6 GoH3 (55) were purchased from Central Laboratory of Blood
Transfusion Service (Netherland RedCross, Amsterdam,The Netherlands) .
Anti-ßl mAb were purified using affinity chromatography on protein
A-Sepharose columns while (F(ab')2 and Fab fragments were prepared as
previously reported (44) .
CellAttachmentAssays
Plasma fibronectin (FN), 38 (FN38), and 80 (FN80) kD proteolytic frag-
ments were kindly provided by Dr. A. Garcia-Pardo (Centra de Investiga-
ciones Biol6gicas, Consejo Superior Investigaciones Cientificas, Madrid) .
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Collagen (COL), type I and type IV, laminin (LN), and fibrinogen (Fg)
were purchased from Sigma Chemical Co. Recombinant soluble VCAM-1
(rsVCAM-1) and ELAM-1 (rsELAM-1) were purified by immunoaffinity
chromatography from conditioned medium ofCHO cells stably transfected
with a truncated cDNA for VCAM-1 (38) and ELAM-1, respectively (37).
The adhesion assays were essentially performed as previously described
(15). Briefly, 96-well flat-bottomed plates (Titertek; Flow Laboratories)
were coated overnight at 4°C with different substrates diluted in PBS with
divalent cations. Thereafter, the plate was washed once with PBS and then
saturated with 1% BSA 1 h at 37°C. The plate was washed twice with PBS
and cells (preincubated with different mAb or medium as control) were
added in serum free medium and incubated for30 min at37°C unless other-
wise indicated. To quantify cell attachment, the plate was washed twice with
PBS, cells were fixed with a mixture ofacetone/methanol 1:1 and dyed with
violetcrystal 0.5% . Then, absorbance at 540 nm was measured in an ELISA
detector (Pasteur Laboratories, Paris, France) and optical density was
found to be practically a linear function of number ofcells by a calibration
curve (optical density vs number of cells) made for each cell type used in
our assays. There was a linear relation in a range from 5 x 103-1.5 x 105
cells (0.013-0.230 OD units) for U-937 and K-562 cells; from 4 x 103-1.2
x 105 cells (0.013-0.270 OD) for A375 cells, and from 3 x 104-4.5 x 105
cells (0.020-0.290 OD) for T lymphocytes. To calculate percentage of at-
tachment, basal adherence to BSA (cell binding to BSA-coated wells was
constant enough for each cell type and was always <2%) was substracted
from attachment values obtained and the final results expressed as percent
control (attachment in mAb-free wells as 100%). The assays were performed
in triplicate. Total cellular inputwas calculated by spinning wells withorigi-
nal number of cell aliquots, then fixing, staining, and measuring OD.
FRCSAnalysis
Fluorescence flow cytometry analysis was performed on a FACScan
cytofluorometer (a registered trademark of Becton Dickinson, Mountain
View, CA). A375 melanoma cells were detached with a solution of 0.05%
Trypsin and 0.02% EDTA (Flow Laboratories) and incubated at 4°C with
100 pl hybridoma culture supernatants, followed by washing and labeling
with fluorescein isothiocyanate-labeled goat anti-mouse Fc specific frag-
ment of Ig. The rat GoH3 mAb anti-a6 was developed by using as second
reagent a mixture of the mouse anti-rat Ig mAb RG7/7.6 and RG7/9.1, spe-
cific for rat kappa chain (58). Data were collected in a logarithmic scale
and percentage of positive cells was obtained by substracting the back-
ground given by the negative control mouse myeloma P3X63.
Indirect Immunofluorescence
After the induction of cell adhesion to FN-coated coverslips with different
reagents, cells were fixed in 3.7% formaldehyde in PBS for 10 min at room
temperature. The cells were permeabilized with 0.2% Triton X-100 in Tris-
buffered saline (TBS: 50 mM Tris-HCI, 150 mM NaCl, 0.1% NaN3, pH
7.6) for 3 min. Cells were stained with the primary antibody diluted in TBS
for 1 h at 37°C, rinsed in TBS and stained with a 1/50 dilution of the appro-
priate secondary antibody. Immunostaining for ßl integrin was performed
using the Alex 1/4 mAb diluted 1:4 in TBS. Polyclonal rabbit anti-talin was
kindly provided by Dr. K. Burridge (University of North Carolina, Chapel
Hill, NC) and diluted 1:300. The secondary antibodies used were: FIX
goat anti-rabbit IgG (Chapel Laboratories), and RITC goat anti-mouse IgG
(Chemicon, Teruecula, CA). For double-label studies, cells were simul-
taneously stained with a mixture of the fluorescent secondary antibodies.
After a final wash, the coverslips were rinsed in deionized water to remove
salts and mounted in Gelvatol (Monsanto, St. Louis, MO). The cells were
observed using a IM-35 photomicroscope (IM-35; Carl Zeiss, Oberkochen,
Germany) with a x 100 oil immersion objective and photographed on
TMAX 400 film (Eastman Kodak Co., Rochester, NY) processed to 800-
1,600 ASA with TMAX developer (Eastman Kodak Co.).
Results
EnhancementofCellBindingto Fibronectin Promoted
byAnti-ßl Antibodies
To study the possible regulatory role of the common 01
subunit of VLA integrins in cell binding to different ECM
components, we first examined the functional effects of
different anti-ßl mAb on the attachment of myelomonocytica
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Figure 1. Effect of anti-01 mAb on the attachment of U-937 cells to plasma fibronectin. U-937 cells were preincubated with different
anti-01 mAb (Lia 112, Lia 115, Alex 114, A-1A5, P4C10, K20, and TS2116) and anti-HLA-A,B mAb (W6132) as well as with 1 /Ag/ml of
purified Ig, F(ab')2 and 10 Wg/ml of Fabfragmentsof anti-01 TS2/16 mAb. The differentanti-ßl mAb were assayed at adose of 1 Ag/ml.
Anti-ßl TS2/16 and Alex 1/4 mAb were assayed in a wide range of doses (from0.1 to 50 Ag/ml) and theireffects were similar to theones
shown in the figure. Then, cellswere assayedfor attachment to 10 ug/ml ofplasma FN for30 min as described in Materials andMethods
(Fig. 1 A). Control without mAb represents 6% of total cellular input. U937 were also assayed (preincubated or not with 1:10 dilution
of the anti-/31 TS2/16 mAb) on plates coated with 10 /ag/ml of plasma FN, 1% BSA, and 500,ug/ml of Fg (Fig. 1 B) . A representative
experiment out of seven independent ones is shown.
U-937 cells to plasma fibronectin. As shownin Fig. 1 A, the
anti-01 Lial/2 andP4C10 mAb inhibited cell binding to FN,
whereas no significant effect was exerted by other anti-01
mAb such as Lial/5, Alex 1/4, or K20. Interestingly, two
anti-01 TS2/16 and A-IA5 n1Ab (IgGI andIgG2b subclasses,
respectively) induced a strong enhancement of cell binding
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to FN. These two anti-01 mAb have been previously de-
scribedas defining an identical or closely related epitope on
ßl chain (25), which is either functionally (Lia 1/2, Lia 1/5,
and Alex 1/4) or topographically (K20) distinct from those
defined by other anti-01 antibodies (data not shown). The
magnitude of this enhancing effect was in a range of six- to
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Figure 2. Kinetics and dose-
dependence of the anti-01-
enhanced binding of U-937
cells to plasma fibronectin.
U-937 cells were incubatedin
the presence (o) or in the ab-
sence (o) of 1 Ag/ml of puri-
fied anti-01 TS2/16 mAb and
then assayed for binding onto
plates coated with 10 Ag/ml of
plasma FN for different times
of incubation (A) or assayedat
several doses of applied plas-
ma FN during 30 min (B).
Percentage of attached cells
respect total cellular input is
shown. Arepresentativeexperi-
ment outofthree independent
ones is shown.H
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eightfold above the basal level of binding obtained either in
the absence ofantibody or in the presence of the anti-HLA-A,
B mAb as control (Fig. 1 A) . This adhesion assay was per-
formed seven different times and the enhancing effect was
always observed although some variability in the level of
anti-ßl-mediated enhancement of U-937 cells attachment to
FN was detected . The effect of anti-01 TS2/16 mAb appears
- AI*x1/4TS2/16TS2/18T32/16
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Figure 4. Anti-ßl mAb enhance the binding of U-937 cells to the
VLA-4 cellular ligand VCAM-1 . U-937 cells were preincubated
with 1 jug/ml of purified Ig of the indicated anti-01 mAb either
alone or combined with anti-a4 HP2/1 or antiVCAM-1 4B9 mAb .
Then, cells were assayed for attachment to plates coated with 5 pg/
ml of recombinant soluble VCAM-1 (rsVCAM-1) . Control without
antibody represents-8.5 % oftotal cellular input . A representative
experiment out of three independent ones is shown .
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Figure 3. Anti-ßl mAb enhance the
binding of U-937 cells to both 38 and
80kD proteolytic fragments offibro-
nectin . U-937 cells were preincubated
with 1 Wg/ml of purified Ig of the in-
dicated anti-01 mAb either alone or
combined with 1 jig/ml ofthe anti-a4
(HP2/1) or anti-a5 (SAM-1) mAb .
Then, cells were assayed for attach-
ment to plates coated with 10 ug/ml
ofFN38 or 1 wg/ml of FN80. Control
without mAb represents 5 and 25
of total cellular input on FN38 and
FN80, respectively . A representative
experiment out of three independent
FN 80
￿
ones is shown .
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to be substratum specific since no significant induction of
cell attachment was observed to plates coated with either
fibrinogen or seroalbumin (Fig . 1 B) .
The upregulatory effect of anti-01 mAb was isotype and
Fc independent and could be observed with purified Ig as
well as with both divalent F(ay)2 and monovalent Fab frag-
ments of the TS2/16 mAb (Fig. 1 A) . Furthermore, ßl-
mediated enhancement of cell attachment occurred very
rapidly, within 5-10 min after anti-01 mAb addition (Fig .
2 A), and was dependent on the concentration of coated FN,
with maximal induction in the range of 5-10 gg/ml of FN
(Fig . 2 B) .
Involvement ofVLA-4 and VLA-5 Integrins in
01-regulated Cell Binding toFN
Since U-937 cells have been previously shown to bear both
VLA-4 and VLA-5 types of fibronectin receptors (20), we
explored whether both integrin members could be impli-
cated in ßl-enhanced cell binding to FN . The anti-01 TS2/16
mAb enhanced cell attachment to two distinct fibronectin
proteolytic fragments of 38 and 80 kD, containing binding
sites forVLAcx4 and cY5, respectively (Fig . 3) . Moreover, ßl-
mediated cell binding to FN38 or FN80 kD was virtually
abrogated by the simultaneous cell treatment with blocking
anti-cA HP2/1 or anti-a5 SAM-1 mAb, respectively (Fig . 3) .
These results clearly demonstrate that ßl-regulated cell bind-
ing to fibronectin involves botha4 anda5 integrin fibronec-
tin receptors .
Upregulation ofVLA-4-mediated Cell Binding to the
Endothelial Ligand VCAM-1
We next investigated the regulatory effect of anti-01 TS2/16
mAb on U-937 cell binding to plates coated with a recom-
binant soluble form of VCAM-1, a cytokine-inducible en-
dothelial cell ligand for theVLA-4 integrin . As shown in Fig .
4, a remarkable increase in cell attachment to VCAM-1 was
observed after cell treatment with anti-01 TS2/16 mAb. Cell
binding to VCAM-1 could be inhibited by either antiVLA-4
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Figure 5. Anti-01 mAb promote specific attachment of resting pe-
ripheral blood T lymphocytes to 38-kD proteolytic fragment of
fibronectin and rsYCAM-1. Purified peripheral blood T cells were
preincubated with 1 hg/ml of purified Ig of anti-ßl TS2/16 andAlex
1/4mAb, or50 ng/ml of PMA. Then, cellswere assayedforbinding
to plates coated with 20,ug/ml FN38, 5 Wg/ml rsVCAM-1, 20 Ag/ml
COL 1, or 5 kg/ml rsELAM-1. Control without mAb represents
11.25 and 10.6% of totalcellular input on FN38 and r§VCAM-1, re-
spectively. The percentage of adhesion to COL I and rsELAM-1 is
referred to those obtained with FN38 or rsVCAM-1, respectively.
Arepresentativeexperiment outofthreeindependent ones is shown.
or antiVCAM4 mAb(Fig. 4). Theseresults clearly indicate,
that mAb to ßl can upregulate cell binding of VLA-4 to its
VCAM-1 counterreceptor on endothelial cells as well as to
fibronectin.
Anti-ßl mAbPromoteAttachmentofResting
TLymphocytes to Both VLA-4Ligands
The functional activity of integrins is regulated during lym-
phocyte activation. Thus, resting peripheral blood T cells
which are unable to bind to VCAM-1 and FN ligands, ac-
quire these VLA-4-mediated capacities aftertreatment with
different stimulating agents (54, 64).
The treatment of purified T lymphocytes with anti-ßl
TS2/16 mAb promoted a strong enhancementof T cell inter-
actions with FN38 and VCAM-1 (Fig. 5). This enhancing
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effect was comparable in magnitude to that triggered by ac-
tivating agents such as phorbol esters (Fig. 5) or anti-CD3
mAb and was VLA-4 mediated since it could be virtually
abrogated by antiVLAcx4 mAb (data not shown) . The en-
hancing effect of anti-ßl TS2/16 mAb was also observed on
T lymphocyte binding to the FN80 proteolytic fragment.
The ßl-mediated increment of T cell attachment to FN80
was threefold above control and was inhibited by anti-ce5
rnAb (data not shown) .
This ßl-mediated regulatory effect was specifically exerted
on VLA-integrin-ligand interactions sinceno effect was ob-
served on lymphocyte binding to either an unrelated en-
dothelial cell adhesion ligand, the selectin SLAM-1, or to
collagen, an ECM protein whose specific receptor (VLA-2)
is not detected on resting lymphocytes (25) (Fig. 5).
01-mediated Increase ofCell Interactions with Other
ECMProteins
To assess whether the observed regulatory effects of anti-ßl
mAb could be also extended to other distinct VLA-mediated
adhesive interactions, we studiedthe attachment of theA375
melanoma cells, which bear both VLA-2 and VLA-6 recep-
tors for Collagen and laminin, respectively (56), to either
collagen type I or laminin in the presence of the anti-ßl
TS2/16 mAb. As observed in Fig. 6 A, binding to both colla-
gen and laminin was notably increased by the incubation
with anti-ßl ml Moreover, ßl-mediated cell binding to
laminin involved the VLA-6 heterodimer since it was
specifically blockedby simultaneous cell incubation with the
antiVLAa6 GoH3 mAb (Fig. 6 A). A similar enhancing
effect of anti-ßl mAb was also observed on T lymphocyte
binding to LN andwas mediated by VLA-6as deducedfrom
theblocking effect of anti-a6 GoH3 mAb. An enhancement
of A375 cell binding to FN, whose receptor in these cells
hasbeen previously described (40), was also observed after
treatment with anti-ßl mAb (data not shown). In contrast,
we cannot conclude that VLA-2 was involved in ßl-mediated
A375 cell binding to collagen since no inhibitory effect was
exerted by the antiVLAc12 PIE6 mAb used (Fig. 6A), thus
implying that other collagen receptor beside VLA-2 couldbe
additionally involved in this particular cell-ECM interac-
tion. These enhancing effects of anti-ßl mAbdo not appear
to involve changes in A375 cell surface membrane expres-
sion of different VLA heterodimers as demonstrated by
quantitative flow cytometry analyses in A375 melanoma
cells(Table 1) . As shown, A375 cells expressed low amounts
of VLA-6 (Thble I), as previously reported (56), that account
for cell binding to LN, as demonstrated by inhibition with
anti-ot6 GoH3 mAb (Fig. 6A). Furthermore, the functional
effects of anti-ßl TS2/16 mAb were also observed in A375
cells previously treated with inhibitors of either protein or
RNA synthesis (data not shown) .
To further substantiate the possible regulatory role of anti-
ßl mAb on VLA-2-collagen interaction, we studied the at-
tachment of K-562 cells transfected with a cDNA encoding
tx2 chain to type I collagen . The enhancing effect of anti-ßl
TS2/16 niAb wasobserved andit couldbe virtually abrogated
by anti-«2 PIE6 mAb indicating that the function of the
VLA-2 heterodimer could be also regulated through the ßl
chain (Fig. 6B). As control of specificity, binding of o4-K-
562-transfected cells to both COL and FN38 were also in-
cluded (Fig. 6 B).
663A 375
MetabolicRequirements ofßl-mediated
TLymphocyte Adhesion
Stimuli CD43 HLA-A,B al a2
- 0(299) 82(637) 1(307)
TS2/16 0(306) 80(646) 0(354)
500
00
100
When the requirements of ßl-mediated functional effects
were investigated in T cells, we found that this process re-
quired an active metabolism, cytoskeleton integrity, physio-
logical levels of intracellular Cat+, and a functional Na-,/H+
antiporter as shown by inhibition experiments. Thus, incuba-
tion of T cells at 4°C or pretreatment of cells with different
agents such as 2 DO-glucose plus sodium azide, cytochalasin
B, Quin-2a, or EPA prevented the enhancing effects of anti-
01 TS2/16 mAb on T cell adhesion to FN (Table II) . These
reagents also inhibited the adhesion induced by other stimuli
such as the Caz+ ionophore A23187 and PMA indicating
that intact cellular metabolism is needed for the induction of
cell adhesiveness. In contrast, pretreatment of T cells with
staurosporine, an specific inhibitor of PKC, did not inhibit
the ßl-mediated regulatory effect, whereas it specifically
abrogated PMA-mediated adhesion (Table II).
We also studied possible intracellular signals involved in
anti-ßl TS2/16 mAb-enhancing effect. No changes in intra-
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Table L Effect ofAnti-ßl mAb on Cell Surface Antigen Expression ofA375 Melanoma Cells
Percent positive cells (MR)
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Figure 6. Anti-01 mAb-mediated attachment of A375 melanoma cells to collagen type I andlaminin andofa2-transfected K-562 to collagen
type I. (A) A375 cells were detached and then preincubated with 1 Ag/ml of indicated anti-01 mAbeither alone or combined with a 1:10
dilution of anti-a2 PIE6 or 1 ttg/ml of anti-a6 GoH3. Then, cells were assayed for attachment to plates coated with 5 Ag/ml of collagen
type I or 10 Ag/ml of laminin. Control without antibody represents 10 and8% of total cellular input on collagen and laminin, respectively.
A representative experiment out of three independent ones is shown. (B) a2- and a4-transfected K-562 were preincubated with 1 Ag/ml
ofpurified Ig of anti-ß1 TS2/16 mAbeither alone or combined with anti-a5 SAM-1 or anti-a2 PlE6. Then, cells were assayed for attachment
to plates coated with 10 Ag/ml of FN38 and/or with 10 /Ag/ml of collagen type I. Control without antibody represents about 6.25 and 1%
of total cellular input for a4-transfected on FN38 and for a2-transfected K-562 on collagen, respectively. A representative experiment
out of three independent ones is shown.
cellular levels of cAMP and Caz+ were observed after treat-
ment of T lymphocytes with anti-ßl TS2/16 mAb (data not
shown) . Only minor alterations of intracellular pH (an in-
crease -0.03-0.06 pH after treatment of T lymphocytes with
TS2/16mAb) couldbe detected, inagreement with results re-
ported in a recent study using the anti-01 TS2/16 mAb (52).
Changes in CellMorphology and Cytoskeletal
Organization Inducedby anti-01 mAbonEndothelial
and U-937Cells
The regulatory effect of the anti-01 on the attachment of an
adherent cell type such as HUVEC to either FN, LN, and
COL type IV was morphologically analyzed. The anti-ßl
TS2/16 mAb not only increased the number of cellsattached
to these ECM proteins but most interestingly, it induced a
dramatic increase in cellular spreading. Thus, endothelial
cellstreated with anti-01 TS2/16 mAb displayed an extended
morphology showing an increased number of cytoplasmic
projections (Fig. 7, A, B, and C), compared to cells bound
in the absence of anti-01 mAb (Fig. 7, D, E, and F) . A rapid
62(388) 69(443) 44(528) 81(548)
60(390) 67(461) 35(490) 77(504)
A375 melanoma cells were preincubated either with medium or with Fab fragment of anti-ßl TS2/16 mAb at 10,ug/nil for 1 h at 37°C and then assayed for antigen
expression as described in Materials and Methods. mAbs used were : TP1/36 (CD43), W6/32 (HLA-A,B) TS2/7 (al), 12F1 (a2), PIB5 (a3), HP2/1 (a4), SAW
(a5), GoH3 ((x6), and TS2/16 (01). Percentage of positive cells and mean of fluorescence intensity (MFI) in logarithmic scale are shown.Table 11. Metabolic Requirements for 01-mediated
Adhesion to Fibronectin of TLymphocytes
T lymphocytes were preincubated with different agents for 30 min at 37°C
(with the exception of control and 4°C samples) at the following doses: 2 DO-
glucose 50 mM + sodium azide 0. I %, cytochalasin B 20 pM,Quin-2a 20 /AM,
N-ethyl,N-propyl amiloride (EPA) 50 /AM, and staurosporine 200 nM. The
different treatment did not significantly affect cellular viability as assessed by
trypan blue staining. Then, cells were stimulated for 30 min at 37°C with no
stimuli, the anti-01 TS2/16 mAbat 10 pg/ml, PMA50 ng/ml or A23187 I 'UM,
and then assayed for attachment on FN-coated plates (20 lpg/ml). Percentage
of cells attached was calculated. A representative experiment out of three is
shown.
clustering and organization of focal adhesions were also ob-
served (data not shown). These results suggested a possible
signalling through ßl chain to interactive cytoskeletal com-
ponents.
Next, we analyzed morphological changes induced in
U-937 cellsby anti-01 TS2/16 mAb, compared to other agents
such as the Cat+ ionophore A23187 or PMA . As observed
in Fig. 8, a dramatic change in U-937 cellular morphology
was observed after anti-01 TS2/16 mAb treatment. After the
induction of adhesion by anti-01 mAb, U-937 cells which are
normally round, extend many long thin protrusions known
as microspikes or filopodia (Fig. 8 E) . These ßl-mediated
morphological changes are distinct from those induced in
U-937 cells by PMA; with this treatment instead of micro-
spikes, cells extend thin sheetlike processes known as lamel-
lipodia (Fig. 8 D). When anti-01 mAb and PMA were used
in combination, greater cell spreading in the form of lamel-
lipodia extension couldbe observed (Fig. 8 F). By contrast,
cells remained unaltered after treatment with the Ca2+ iono-
phore A23187 or the anti-01 Alexl/4 mAb included as con-
trol (Fig. 8, C and B, respectively). These data point out the
possibility of different pathways for the transduction of ad-
herent signals in U-937 cells.
Kinetics studies indicated that the morphological changes
induced in U-937 cells by anti-01 TS2/16 mAb were time de-
pendent (Fig. 9, left), correlating with the kinetics of the en-
hancing effects triggered by anti-01 mAb on U-937 cell adhe-
sion to FN (Fig. 2 A) . The appearance of microspikes could
be observed as early as 5 min after TS2/16 mAb addition.
Furthermore, both the ßl integrin and the cytoskeletal pro-
tein talin colocalized in the TS2/16-induced microspikes
(Fig. 9, right), suggesting that anti-01 regulatory effect on
cell adhesion could be associated with organization of cyto-
skeleton. These results emphasize the central role of the
common 01 chain in the regulation of different adhesive
functions of VLA integrins as well as its implication in con-
trolling cell shape.
Discussion
Our results support a pivotal role of VLA ßl chain in the
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regulation of adhesion receptor functions of different VLA
heterodimers. We have found that certain ßl antibodies can
promote VLA-mediated cell binding to both ECM and cellu-
lar ligands. Recent studies have described several antibodies
against integrin a subunits that induce changes in recep-
tor-ligand interactions (5, 11, 23, 32, 59). Herein, we have
identified two antibodies, TS2/16 and A-IA5 specific for the
ßl chain of VLA integrins, that induce an enhancement of
VLA receptor-ligand binding affinities. The engagement of
distinct ßl epitopes seems to modulate in a different manner
VLA-mediated adhesion functions. Hence, TS2/16 mAb,
which increased cell attachment to different ECM ligands,
is also able to inhibit VLA-4-mediated cell-cell aggregation
(11). Conversely, the Lia 1/2 and P4C10 niAb inhibit cell at-
tachment to ECM, and other ßl antibodies, Alex 1/4, Lia
1/5, and K20, did not affect cell attachment. Thus, these
results clearly show that the upregulatory effect of anti-01
mAb appears to be site specific and document the existence
of a differential pattern of functional involvement associated
with each 01 epitope.
The anti-ßl-enhanced cell binding appears to be isotype
and Fc independent and can be also triggered by both diva-
lent and monovalent Fab fragments. The ßl regulatory effect
is promoted in a dose dependence of ligand and does not re-
quire de novo protein synthesis since it follows a very rapid
kinetics and could be observed in the presence of inhibitors
of protein and RNA synthesis. Moreover, the ß1-mediated-
enhanced adhesion does not involve any associated change
in cell surface expression of the different VLA heterodimers.
This is similar to the regulatory effects previously described
with either antibodies specific for some integrin a subunits
or specific ligands (5, 11, 16, 23, 32, 59) . Taken together,
these results suggest that anti-01 mAb could function by in-
creasing the affinity of different VLA aßl heterodimers for
their respective ligands.
The enhancement of affinity promoted by anti-01 mAb is
not restricted to a unique member of VLA integrins nor t6-
a single substrate. The ßl-regulatory effects have been ob-
served with at leastVLA-2, VLA-4, VLA-5, and VLA-6 het-
erodimers and with ECM proteins (FN, COL, and LN) as
well as cellular ligands (VCAM-1). These effects have been
shown to be substratum specific because they are only
promoted on substrates known to be ligands of VLA inte-
grins.
It has been previously reported that the ligand affinity of
several integrins from the 02 (LFA-1, Mac-1) (2, 17), 03
(gpIIb/IIIa) (16, 45), and more recently from the ßl family
(VLA-4, VLA-5, and VLA-6) (53, 54) can be regulated by
different stimuli. We report herewith that the interaction
of VLA integrins with their ligands can be also regulated
through the common ßl chain. The anti-ßl-mediated regula-
tory effects are exerted on different cell types including the
U-937 myelomonocytic cell line, melanoma cells, a2- and
a4-transfected K-562 cells, HUVEC, and normal resting pe-
ripheral blood T cells. In resting lymphocytes, the anti-01
mAb promoted VLA-4-mediated cell attachment to its two
ligands, VCAM-1 and the FN38 proteolytic fragment con-
taining CS-1 region as well as to FN80 and LN (ligands for
VLA-5 and VLA-6, respectively), in a similar manner to that
described with activating agents such as phorbol esters or
anti-CD3 mAb (53, 54) .
The ß and a chains of integrins could contribute to both
binding of ligands, as demonstrated for 03 subunit (6), and
665
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Percent cell attachment
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.the transduction of intracellular signals (33, 52, 63, 66) . Re-
cently, the ßl chain has been also shown to regulate different
cellular functions since anti-(31 mAb induce comitogenic
proliferative signals on T lymphocytes (65) and increase at-
tachment of neuronal cells to laminin and collagen (42) .
These observations are in line with results reported here,
supporting a central role of ßl chain in regulating VLA-
mediated interactions .
Possible mechanisms accounting for the ßl-mediated en-
hancement of VLA-ligand interactions include : (a) a confor-
mational change on the aß heterodimer as a result of the
binding of anti-ßl mAb resulting in a higher affinity form of
the integrin that enables the interaction with ligand(s) . This
putative conformational change affects the a chain since the
anti-ßl-mediated effect could be abrogated by specific anti-
VLAc« antibodies . In fact, conformational changes mediated
by either anti-integrinmAb or ligand binding have been pre-
viously reported for the LFA-1, Mac-1, and gpIlb/IUa inte-
grins (2, 16, 17, 45, 59) ; and (b) the binding ofanti-ßl mAb
may trigger intracellular signals . In this regard, it has been
recently described that insoluble FN as well as antibodies
specific for ßl chain activate the Na+/H+ antiporter (52) .
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Figure 8 . Morphological
changes induced in U-937
cells by different reagents that
promote the adhesion to FN .
Cells were treated for 2 h with
the following reagents : no
treatment (A), 1 jAg/ml Alex
1/4 anti-ßl mAb (B), 1 AM
A23187 calcium ionophore
(C), 50 ng/ml PMA (D), 1
,g/ml TS2/16 mAb (E), or a
mixture of 20 ng/ml PMA
plus lug/ml TS2/16mAb (F) .
Then cells were fixed and
stained by immunofluores-
cence for ßl integrin with
anti-ßl Alex 1/4 mAb. Bar,
20 jm .
Moreover, clustering of ßl chain integrins also increased
protein tyrosine phosphorylation (33) . Whether these intra-
cellular signallings are accounting for our observations on
ßl-mediated VLA-ligand adhesive interactions still remains
unclear. When we explored intracellular signals triggered on
T lymphocytes by anti-ßl TS2/16 mAb, no changes in second
messengers such as intracellular cAMP and calcium levels
were detected . By contrast, a small increase in intracellular
pH could be detected under the same conditions, in agree-
ment with previous reported data (52) . However, our data
using inhibitors of different signal transduction pathways
point out to a general requirement of an intact metabolism
for regulation of cell adhesiveness by different stimuli in-
stead of ascribing a specific mechanism for ßl-mediated
effects . It is also conceivable that both putative mechanisms,
i.e., modification ofassociateda chains and signal transduc-
tion, might be acting in concert .
Evidence suggesting a role for VLA-5 FN receptor in
regulating cell spreading and migration, matrix assembly,
and cytoskeletal organization has been previously described
(1, 41) . In this context, it is important to remark on our ob-
servations concerning the changes induced by anti-ßl TS2/16
667Figure 9. Time-course ofmor-
phological changes promoted
by anti-01 mAb on the attach-
mentof U-937 cells toFN and
participation of cytoskeletal
proteins in these morphologi-
cal changes . (Left) U-937 cells
were incubated in the absence
(A) or in the presence (B, C,
and D) of the anti-01 TS2/16
mAb for different periods of
time : 5 min, 30 min and 2 h
(B, C, and D, respectively), on
FN-coated coverslips . Cells
were fixed and stained by im-
munofluorescence for 01 in-
tegrin with anti-ßl Alex 1/4
mAb . (Right) U-937 cells
were cultured for 2 h in the
presence of TS2/16 mAb on
FN-coated coverslips . Cells
were fixed, permeabilized,
and stained by double-label
immunofluorescence for 01
integrin with anti-01 Alex 1/4
mAb (A) and for talin (B) .
Note that the integrin and the
talin colocalize at the micro-
spikes . Bar, 20 pm .
mAb on both cell morphology and organization ofcytoskele-
ton . The interaction of the cytoplasmic tail of ßl chain with
the cytoskeletal proteins talin and a-actinin involved in orga-
nization of actin microfilaments as well as in the regulation
of cellular shape and motility has been previously docu-
mented (9, 10, 28, 43) . Our data showing the colocalization
ofboth ßl integrin and talin at the 01-induced cellular micro-
spikes indicate a regulatory role of 01 chain in cell shape.
Moreover, both ßl-mediated effects, enhancement of cell ad-
hesion and morphological changes, display similar kinetics
and thus, they appear to happen coordinately. On the other
hand, the ßl-mediated induction of microspikes (filopodia)
on U-937 cells is clearly different from morphological
changes, mainly involving lamellipodia formation, triggered
by other stimuli as phorbol esters. Although both anti-01
TS2/16 mAb and phorbol esters induced cell adhesiveness,
they appear to exert their effects through distinct mecha-
nisms as evidenced by both the observed morphological
differences and the selective inhibitory effect of protein ki-
naseC specific inhibitors in phorbol ester-mediated cellular
adhesiveness.
It is worth emphasizing the essential role that the 01 chain
plays in regulating the affinities of VLA integrins for their
ligands . This fact could be of physiological relevance in the
regulation of the adhesive and tissue infiltrating properties
of leukocytes as well as the metastatic capacities of tumor
cells. For example, the regulation through 01 chain ofVLA-4
interaction with its counterreceptor VCAM-1 on activated
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endothelial cells could be of crucial importance for binding
and migration of leukocytes at sites of tissue inflammation .
Furthermore, it also might be of relevance in regulating the
metastatic properties of some tumors such as melanoma
cells, since this receptor-counterreceptor pair represents the
only adhesion pathway used by melanoma cells to adhere to
endothelium in vitro (39, 49) .
Finally, our finding that anti-01 mAb enhance both cell at-
tachment and spreading and cytoplasmic extension of en-
dothelial cells to different ECM proteins such as COL, LN,
and FN could be also physiologically important . It might
represent a mechanism to regulate and modify the process
of tissue repair that takes place in injured vessels . There is
increasing evidence that the cell migration that takes place
during tissue repair such as wound healing depends on
integrin-mediated interactions (14, 30) . Therefore, 01-regu-
lated increases in endothelial cell adhesion to ECM proteins
may allow for a better attachment, migration, and differenti-
ation, thus minimizing the exposure of subendothelium to
platelets and procoagulant factors that could provoke throm-
botic processes.
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